China NT Pharma Group Co. Ltd. has reported the successful completion of a profit guarantee for its Associate's Miacalcic business for the years 2021 through 2023. The consolidated net profit figures for these years exceeded the guaranteed amounts set in the agreement with Konruns Pharma. In 2021, the Miacalcic business recorded a net profit of RMB81.31 million and RMB81.59 million after accounting for non-operating profit and loss, surpassing the guaranteed profit of RMB80 million by RMB1.31 million. This represents 101.64% of the projected profit for that year. For the year 2022, the net profit was RMB102.69 million, reaching RMB102.02 million after adjustments, exceeding the guaranteed RMB100 million by RMB2.02 million, or 102.02% of the projected profit. In 2023, the net profit amounted to RMB122.89 million and RMB122.87 million after adjustments, surpassing the guaranteed amount of RMB120 million by RMB2.87 million, achieving 102.39% of the projected profit. Overall, the Group has fulfilled its profit guarantee obligation, achieving a total net profit after tax of not less than RMB300 million over the three years. This announcement underscores the financial stability and performance of the Associate's Miacalcic business within the specified period.